These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 26501109)

  • 21. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine.
    Block SL; Brown DR; Chatterjee A; Gold MA; Sings HL; Meibohm A; Dana A; Haupt RM; Barr E; Tamms GM; Zhou H; Reisinger KS
    Pediatr Infect Dis J; 2010 Feb; 29(2):95-101. PubMed ID: 19952863
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reported adverse events in girls aged 13-16 years after vaccination with the human papillomavirus (HPV)-16/18 vaccine in the Netherlands.
    van Klooster TM; Kemmeren JM; van der Maas NA; de Melker HE
    Vaccine; 2011 Jun; 29(28):4601-7. PubMed ID: 21549785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hazard of complex regional pain syndrome following human papillomavirus vaccination among adolescent girls in the United States: a case-cohort analysis of insurance claims data.
    Vielot NA; Becker-Dreps S
    Expert Opin Drug Saf; 2020 Jan; 19(1):107-112. PubMed ID: 31674255
    [No Abstract]   [Full Text] [Related]  

  • 24. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.
    Apter D; Wheeler CM; Paavonen J; Castellsagué X; Garland SM; Skinner SR; Naud P; Salmerón J; Chow SN; Kitchener HC; Teixeira JC; Jaisamrarn U; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Mindel A; de Sutter P; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G;
    Clin Vaccine Immunol; 2015 Apr; 22(4):361-73. PubMed ID: 25651922
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix]: profile report.
    Keam SJ; Harper DM
    BioDrugs; 2008; 22(3):205-8. PubMed ID: 18481902
    [No Abstract]   [Full Text] [Related]  

  • 26. A cluster analysis of serious adverse event reports after human papillomavirus (HPV) vaccination in Danish girls and young women, September 2009 to August 2017.
    Ward D; Thorsen NM; Frisch M; Valentiner-Branth P; Mølbak K; Hviid A
    Euro Surveill; 2019 May; 24(19):. PubMed ID: 31088598
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Co-administration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls.
    Schmeink CE; Bekkers RL; Josefsson A; Richardus JH; Berndtsson Blom K; David MP; Dobbelaere K; Descamps D
    Vaccine; 2011 Nov; 29(49):9276-83. PubMed ID: 21856349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reports of Postural Orthostatic Tachycardia Syndrome After Human Papillomavirus Vaccination in the Vaccine Adverse Event Reporting System.
    Arana J; Mba-Jonas A; Jankosky C; Lewis P; Moro PL; Shimabukuro TT; Cano M
    J Adolesc Health; 2017 Nov; 61(5):577-582. PubMed ID: 29061232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in healthy Chinese women from Hong Kong.
    Ngan HY; Cheung AN; Tam KF; Chan KK; Tang HW; Bi D; Descamps D; Bock HL
    Hong Kong Med J; 2010 Jun; 16(3):171-9. PubMed ID: 20519752
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HPV 6,11,16,18 vaccine: pharmacovigilance reports in 2007.
    Prescrire Int; 2008 Aug; 17(96):160. PubMed ID: 19496245
    [No Abstract]   [Full Text] [Related]  

  • 31. Evaluation of bivalent human papillomavirus (HPV) vaccine safety and tolerability in a sample of 25 year old Tuscan women.
    Levi M; Bonanni P; Burroni E; Bechini A; Boccalini S; Sani C; Bonaiuti R; Indiani L; Azzari C; Lippi F; Carozzi F;
    Hum Vaccin Immunother; 2013 Jul; 9(7):1407-12. PubMed ID: 23571176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP).
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 May; 59(20):626-9. PubMed ID: 20508593
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
    David MP; Van Herck K; Hardt K; Tibaldi F; Dubin G; Descamps D; Van Damme P
    Gynecol Oncol; 2009 Dec; 115(3 Suppl):S1-6. PubMed ID: 19217149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
    Demarteau N; Van Kriekinge G; Simon P
    Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously vaccinated adult women.
    Moscicki AB; Wheeler CM; Romanowski B; Hedrick J; Gall S; Ferris D; Poncelet S; Zahaf T; Moris P; Geeraerts B; Descamps D; Schuind A
    Vaccine; 2012 Dec; 31(1):234-41. PubMed ID: 23063422
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice.
    Han JE; Wui SR; Park SA; Lee NG; Kim KS; Cho YJ; Kim HJ; Kim HJ
    Vaccine; 2012 Jun; 30(28):4127-34. PubMed ID: 22561312
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
    Jenkins D
    Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adverse events following immunization in Ontario's female school-based HPV program.
    Harris T; Williams DM; Fediurek J; Scott T; Deeks SL
    Vaccine; 2014 Feb; 32(9):1061-6. PubMed ID: 24440208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging.
    Lowy DR; Herrero R; Hildesheim A;
    Lancet Oncol; 2015 May; 16(5):e226-33. PubMed ID: 25943067
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
    Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E
    Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.